dalcetrapib   Click here for help

GtoPdb Ligand ID: 12972

Synonyms: JTT-705 | JTT705 | RO-4607381 | RO4607381
Compound class: Synthetic organic
Comment: Dalcetrapib (JTT-705) is a cholesteryl ester transfer protein (CETP) inhibitor thioester prodrug. This class of agent was predicted to increase circulating HDL cholesterol as a mechanism to improve cardiovascular health. Dalcetrapib is one of several CETP inhibitors that have failed to demonstrate efficacy in clinical studies [1-4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 71.47
Molecular weight 389.6
XLogP 5.93
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC(CC)CC1(CCCCC1)C(=O)NC2=C(C=CC=C2)SC(=O)C(C)C
Isomeric SMILES CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
InChI InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)
InChI Key YZQLWPMZQVHJED-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Despite clinical development of CETP inhibitors being widely discontinued (due to lack of significant efficacy), there is a single phase 3 trial of dalcetrapib that is ongoing in a defined subset of patients carrying the rs1967309 alteration ('AA' genotype) in the ADCY9 gene [5].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05918861 Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS Phase 3 Interventional DalCor Pharmaceuticals
NCT02525939 Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS Phase 3 Interventional DalCor Pharmaceuticals 4